<DOC>
	<DOCNO>NCT01012557</DOCNO>
	<brief_summary>Pregnant woman particular risk imminent H1N1v influenza pandemic . The new H1N1v virus require urgent political medical decision vaccination strategy order minimize severe disease death pandemic . However , lack evidence build decision upon . A vaccine provide fourth quarter 2009 , little knowledge immunogenicity . Particularly clinical effectiveness duration immunity pregnant woman newborn infant unknown . Therefore , important study optimal vaccination regimen respect dose use adjuvant decide future health policy vaccination pregnant woman . We unique possibility study aspect H1N1v infection pregnant woman ongoing unselected , prospective , birth-cohort study recruit 800 pregnant mother Q1- 2009 Q4-2010 . Pregnant woman East-Denmark enrol 2nd trimester infant undergo close clinical follow-up . The H1N1v pandemic expect reach Denmark Q4-2009 . The timing enrollment imminent pandemic allow `` experiment nature '' whereby first half mother complete pregnancy H1N1v pandemic . The half cohort pregnant H1N1v prevalent community require H1N1v vaccination . The aim randomize , control , trial compare evaluate dose-related immune protection confer vaccine adjuvant ( Novartis vaccine Focetria ) pregnant woman non-pregnant woman . In addition protocol ass passive immunity confer newborn vaccine regime . The study provide evidence-based guidance health policy vaccination population pregnant woman future H1N1v pandemic .</brief_summary>
	<brief_title>H1N1v Vaccination Pregnant Women : A Longitudinal Cohort Study Characterizing Influenza A H1N1v Vaccination Pregnant Women</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>MF59 oil emulsion</mesh_term>
	<criteria>Healthy pregnant non pregnant woman live Eastern Denmark Fluent Danish Heart disease , endocrine disease , tuberculosis sarcoidosis . History anaphylaxis , serious vaccine reaction , hypersensitivity influenza viral protein , excipients , egg ( include ovalbumin ) , chicken protein .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>H1N1v</keyword>
	<keyword>vaccine</keyword>
	<keyword>pregnant</keyword>
	<keyword>woman</keyword>
	<keyword>Assess whether adjuvanted vaccine offer meaningful benefit pregnant woman term immune response non-adjuvanted vaccine .</keyword>
	<keyword>Assess persistence immune response 15 month time period one single vaccination pregnant mother .</keyword>
	<keyword>Assess whether immune response H1N1 pregnant woman different non-pregnant woman similar age .</keyword>
	<keyword>Gain insight safety Novartis egg-based MF59 adjuvanted H1N1 vaccine Focetria pregnant woman baby .</keyword>
	<keyword>Assess maternally transfer specific antibody H1N1v newborn</keyword>
	<keyword>Passive immunity transfer infant .</keyword>
</DOC>